- Business
- China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SS) is a leading China-based pharmaceutical company primarily engaged in the research, development, production, and sale of innovative chemical drugs and formulations; its core businesses span three key segments including chronic disease medications for blood pressure, lipid, and glucose control such as compound reserpine amphoteridine tablets (No. 0), gliquinone tablets, amlodipine benzenesulfonate tablets (diazepine), valsartan capsules (Hoetsu), valsartan hydrochlorothiazide tablets (fujiyue), irbesartan dispersible tablets, nifedipine sustained-release tablets (II) (beciline), and nifedipine controlled-release tablets (betsicon); specialist drugs targeting cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia, and respiratory areas; and infusion products encompassing basic infusion, therapeutic infusion, and nutritional infusions like citicoline sodium tablets (Novartis); the company also produces active pharmaceutical ingredients (APIs) and pharmaceutical equipment. Founded in 1939 and headquartered at No. 1, Lize East 2nd Road, Beijing, China, it operates 24 subsidiaries with approximately 13,414 employees, serving primarily the domestic market across major therapeutic categories such as anti-influenza, antihypertensives, antibiotics, oncology, anti-infection, and more, while maintaining strong channel coverage, cost control, and internationalization capabilities as a subsidiary of Beijing Pharmaceutical Group Co., Ltd. In recent developments, the company completed the acquisition of 100% stake in China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group for CNY 3.1 billion in March 2024, consolidating its chemical drugs business and enhancing synergies; it reported 2024 revenue of RMB 11.21 billion and net profit of RMB 1.65 billion, reflecting robust growth in its formulation, chronic disease, specialty, and infusion segments; additionally, it continues to invest over 10% of annual revenue in R&D, supporting new drug innovation and market expansion.